Sarepta's Path towards Approval for SRP-9001

---

Print Email

---

Sarepta Therapeutics regarding SRP-9001 heralds a significant advancement in the field of precision genetic medicine for Duchenne muscular dystrophy (DMD). With their global development efforts and collaborative initiatives, Sarepta is poised to make a lasting and positive impact on the lives of DMD patients worldwide, offering hope and the promise of a brighter future.

• Sarepta Therapeutics recently announced a substantial update regarding the Biologics License Application (BLA) for SRP-9001 (delandistrogene moxeparvovec). This innovative therapy is currently undergoing thorough evaluation for its potential in treating ambulant individuals diagnosed with DMD and who carry a confirmed mutation of the DMD gene.
• The company's collaboration with the U.S. Food and Drug Administration (FDA) has yielded promising developments that could potentially transform the lives of young DMD patients.
• After engaging in productive conversations with the FDA, Sarepta Therapeutics received positive signals suggesting that, once the BLA review is concluded, the Agency is actively considering the possibility of granting an accelerated approval for SRP-9001.
• Initially, this approval would be for the treatment of Duchenne patients aged 4-5 years old, representing a critical step forward in addressing the urgent medical needs of this specific age group.
• The EMBARK trial, a multinational Phase 3 study, has been carefully crafted as a randomized, double-blind, and placebo-controlled investigation to evaluate the effectiveness of SRP-9001. Enrollment for this study has been successfully completed, and preliminary findings are anticipated to be disclosed in the last quarter of 2023. Notably, the FDA has communicated to Sarepta Therapeutics that, in addition to validating the outcomes of the initial BLA approval, they are open to exploring the possibility of expanding the label for SRP-9001 based on a comprehensive assessment of the EMBARK data.
• This potential expansion would aim to remove the age restrictions associated with the therapy, providing hope for broader access and improved outcomes for DMD patients.
• Sarepta Therapeutics has received notification from the FDA indicating that a slight extension of time is needed to finalize the review process. This extension includes discussions on postmarketing commitments and negotiations regarding the final label. It is expected that the comprehensive review will be concluded by June 22, 2023.
• This additional time allows the FDA and Sarepta to collaborate effectively, ensuring that all necessary considerations are made to facilitate the approval of SRP-9001 while upholding the highest standards of safety, efficacy, and patient well-being.
• Sarepta, responsible for the global development and manufacturing of SRP-9001, plans to commercialize this promising therapy in the United States upon FDA approval. Recognizing the importance of expanding access beyond U.S. borders, Sarepta entered into a strategic partnership with Roche in December 2019.
• BioIntel360 suggests that recent development Sarepta Therapeutics regarding SRP-9001 signifies a major breakthrough in the field of precision genetic medicine for DMD. This update brings forth a renewed sense of optimism for patients and their families who have been eagerly awaiting innovative treatments for this debilitating disease. The potential for accelerated approval, subject to the completion of the BLA review, is a testament to the unwavering dedication of both Sarepta and the FDA in their mission to make effective therapies accessible to individuals with DMD. Moreover, the FDA's indication to consider expanding the therapy's label beyond age restrictions based on the review of EMBARK data is a promising development. This potential expansion holds the potential to open doors for a wider range of DMD patients, granting them access to this life-altering therapy. This devastating disease not only affects the physical abilities of patients but also has a profound impact on their overall quality of life. BioIntel360 believes that by targeting the underlying cause of DMD and producing functional components of dystrophin in muscle tissue, SRP-9001 has the potential to revolutionize the lives of patients, slowing down the progression of the disease and improving their mobility and overall well-being.